| Style | Citing Format |
|---|---|
| MLA | Azimi F, et al.. "Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231." BMC Complementary Medicine and Therapies, vol. 26, no. 1, 2026, pp. -. |
| APA | Azimi F, Shahverdi A R, Shamsnia H S, Yazdi M H (2026). Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231. BMC Complementary Medicine and Therapies, 26(1), -. |
| Chicago | Azimi F, Shahverdi A R, Shamsnia H S, Yazdi M H. "Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231." BMC Complementary Medicine and Therapies 26, no. 1 (2026): -. |
| Harvard | Azimi F et al. (2026) 'Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231', BMC Complementary Medicine and Therapies, 26(1), pp. -. |
| Vancouver | Azimi F, Shahverdi A R, Shamsnia H S, Yazdi M H. Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231. BMC Complementary Medicine and Therapies. 2026;26(1):-. |
| BibTex | @article{ author = {Azimi F and Shahverdi A R and Shamsnia H S and Yazdi M H}, title = {Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231}, journal = {BMC Complementary Medicine and Therapies}, volume = {26}, number = {1}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Azimi F AU - Shahverdi A R AU - Shamsnia H S AU - Yazdi M H TI - Umbelliprenin Co-Formulated With Selenium Nanoparticles Downregulates Mmp-2, Mmp-9 and Icam-1 Expression in Triple-Negative Breast Cancer Cells Mda-Mb-231 JO - BMC Complementary Medicine and Therapies VL - 26 IS - 1 SP - EP - PY - 2026 ER - |